Business Context and Reporting Period
Company: Anavex Life Sciences Corp. (AVXL)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2008
Business Overview: Anavex is a development-stage biotechnology company focused on researching and developing novel drug targets for the treatment of cancer and diseases of the central nervous system (CNS). The company acquired three patents and one patent application in 2007 and currently has several compounds in pre-clinical stages. It has no commercial products and has not generated any revenue since its inception in 2004.
Key Financial Metrics
| Metric | Year Ended Sept 30, 2008 | Year Ended Sept 30, 2007 |
|---|---|---|
| Revenue | $0 | $0 |
| Total Expenses | $5,281,213 | $1,581,230 |
| Net Loss | $(5,351,269) | $(1,579,993) |
| Accumulated Deficit (Inception to Date) | $(7,062,814) | $(1,711,545) |
| Cash and Cash Equivalents | $6,357 | $25 |
| Working Capital | $(2,293,032) | $(462,504) |
| Current Liabilities | $2,299,389 | $462,529 |
| Promissory Notes Payable | $1,550,000 | $0 |
| Net Cash Used in Operating Activities | $(2,474,053) | $(325,250) |
| Net Cash Provided by Financing Activities | $2,481,467 | $313,000 |
Material Changes vs. Prior Period
- Expense Surge: Total operating expenses increased by approximately $3.7 million (234%) compared to the prior year, driven primarily by a $1.7 million increase in consulting fees and a $520,000 increase in research and development costs.
- Debt Issuance: The company incurred $1.55 million in promissory notes payable during the fiscal year, a significant increase from zero in the prior year. $1.45 million of this debt is due December 31, 2008, which management does not expect to repay on time without extension.
- Stock-Based Compensation: Significant non-cash expenses were recognized for stock-based compensation ($1.68 million) and shares issued for consulting services and severance, reflecting increased reliance on equity to fund operations.
- Liquidity: While cash on hand increased slightly to $6,357, the working capital deficit widened significantly due to the accumulation of debt and accounts payable.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The company's independent auditors have issued a "going concern" opinion, stating that the company's history of losses and lack of revenue raise substantial doubt about its ability to continue operations. The company requires approximately $5.18 million for the 12 months ending September 30, 2009, to fund its plan of operations.
Outlook: Management intends to raise additional funds through private placements, public offerings, or debt financing. There is no assurance that such funding will be available on acceptable terms. The company plans to begin clinical phase trials on its most advanced compounds in 2009.
Risks:
- Capital Shortfall: Failure to secure additional financing could force the company to cease operations.
- Development Risk: All compounds are in pre-clinical stages; there is no guarantee they will prove effective or receive regulatory approval.
- Internal Controls: Management concluded that disclosure controls and internal controls over financial reporting were not effective as of September 30, 2008, citing material weaknesses including a lack of independent audit committee members and insufficient segregation of duties.
- Debt Default: The company is in default on certain promissory notes and expects to negotiate extensions for debt due in December 2008.
Investor Verification Checklist
- Capital Adequacy: Verify if the company has secured the estimated $5.18 million required for the upcoming fiscal year to avoid insolvency.
- Debt Status: Confirm the status of the $1.55 million in promissory notes, specifically whether extensions were granted for the $1.45 million due December 31, 2008.
- Internal Controls: Assess the progress of remediation plans for the identified material weaknesses in internal controls and the appointment of independent audit committee members.
- R&D Milestones: Monitor the transition of compounds from pre-clinical to clinical trials as planned for 2009.
- Related Party Transactions: Review the significant consulting fees and stock issuances to directors and officers, which comprised a large portion of operating expenses.